Pr Rueckert - IXICO Plc CoFounder Board

All Insiders . USA . 
Stock . IXICO plc . Stakeholders . Insider . Pr Rueckert
PHYOF Stock  USD 0.07  0.00  0.00%   

Insider

Pr Rueckert is CoFounder Board of IXICO plc
Phone44 20 3763 7499
Webhttps://ixico.com

IXICO Plc Management Efficiency

The company has return on total asset (ROA) of 0.0393 % which means that it generated a profit of $0.0393 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0861 %, meaning that it generated $0.0861 on every $100 dollars invested by stockholders. IXICO Plc's management efficiency ratios could be used to measure how well IXICO Plc manages its routine affairs as well as how well it operates its assets and liabilities.
IXICO plc has accumulated 545 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. IXICO plc has a current ratio of 5.84, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist IXICO Plc until it has trouble settling it off, either with new capital or with free cash flow. So, IXICO Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like IXICO plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for IXICO to invest in growth at high rates of return. When we think about IXICO Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jeremy CPARelief Therapeutics Holding
33
Dorian BevecRelief Therapeutics Holding
65
Christopher WickRelief Therapeutics Holding
N/A
Serene MPHRelief Therapeutics Holding
N/A
Larry JonesBiostem Technologies
N/A
Anthony GoodImugene Limited
N/A
Drew CroninFineRelief Therapeutics Holding
N/A
Ursula McCurryImugene Limited
N/A
Irmgard MDBiostem Technologies
N/A
Anthony KimRelief Therapeutics Holding
51
Keith MarchiandoZivo Bioscience
63
Dr BScImugene Limited
N/A
David McCulloughRelief Therapeutics Holding
N/A
Jeremy MeinenRelief Therapeutics Holding
32
BSc BVScStarpharma Holdings
59
PharmD MBAImugene Limited
N/A
Jack MBARelief Therapeutics Holding
67
Michael CPABiostem Technologies
N/A
DPhil MBARelief Therapeutics Holding
60
BA ASiAImugene Limited
67
David WoynarowskiBiostem Technologies
N/A
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom. IXICO PLC operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 93 people. IXICO plc [PHYOF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity0.0861
Return On Asset0.0393

IXICO plc Leadership Team

Elected by the shareholders, the IXICO Plc's board of directors comprises two types of representatives: IXICO Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IXICO. The board's role is to monitor IXICO Plc's management team and ensure that shareholders' interests are well served. IXICO Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IXICO Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Austin, Director Technology
Pr Hawkes, CoFounder Board
Giulio Cerroni, CEO, Director
Pr Hajnal, CoFounder Board
Pr Rueckert, CoFounder Board
Robin Wolz, Chief Officer
Hannah Esfahanian, HR Mang
Grant Nash, Company CFO
Marcus Thornton, Chief Officer
Pr Hill, CoFounder Relations

IXICO Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is IXICO Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0861
Return On Asset0.0393
Profit Margin0.12 %
Operating Margin0.11 %
Current Valuation8.91 M
Shares Outstanding48.35 M
Shares Owned By Insiders26.91 %
Shares Owned By Institutions57.90 %
Price To Earning12.50 X
Price To Book1.10 X

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce

Other Information on Investing in IXICO Pink Sheet

IXICO Plc financial ratios help investors to determine whether IXICO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in IXICO with respect to the benefits of owning IXICO Plc security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY